Daniel Rosebrock

PhD student
inactive
(030) 8413 1147

Curriculum Vitae

  • 2013: Bachelor in Mathematics and German at Tufts University, Medford, MA, USA
  • 2015: Master in Mathematics at Tufts University, Medford, MA, USA
  • 2015-2018: Associate computational biologist at Broad Institute, Cambridge, MA, USA
  • Since 2018: PhD student at the IMPRS-CBSC

Publications

  • B Chapuy et al. (2018)
    Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
    Nat Med., 24 (5): 679-690
  • NJ Haradhvala et al. (2018)
    Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair.
    Nat Commun., 9 (1): 1746
  • RK Gopal et al. (2018)
    Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hürthle cell carcinoma.
    Cancer Cell, 34 (2): 242-255
  • C Börgers, RM Takeuchi, D Rosebrock (2018)
    On rhythms in neuronal networks with recurrent excitation.
    Neural Comput., 30 (2): 333-377
  • PK Brastianos*, N Nayyar*, D Rosebrock*, I Leshchiner* et al. (2017)
    Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens.
    NPJ Precis Oncol., 1 (1): 33
  • DA Landau, C Sun, D Rosebrock et al. (2017)
    The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
    Nat Commun., 8 (1): 2185
  • VA Adalsteinsson et al. (2017)
    Scalable whole-exome sequencing of cell-free DNA reveals high concordane with metastatic tumors.
    Nat Commun., 8 (1): 1324
  • M Sade-Feldman et al. (2017)
    Resistance to checkpoint blockade therapy through inactivation of antigen presentation.
    Nat Commun., 8 (1): 1136
  • P Polak et al. (2017)
    A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
    Nat Genet., 49 (10): 1476-1486
  • DA Landau et al. (2015)
    Quantitative clonal dynamics define mechanisms of CLL evolution in response to combination chemotherapy.
    Blood, 126: 362
Go to Editor View